("Summit" or the "Company")
SUMMIT THERAPEUTICS FILES US ANNUAL REPORT FORM 20-F
Oxford, UK, 8 May 2015 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, provides notification that the Company filed on 7 May 2015 its US Annual Report on Form 20-F for the year ended 31 January 2015 with the US Securities and Exchange Commission ("SEC").
This document is now available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.
- END -
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit
is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the
infectious disease C. difficile infection. Further information is available at www.summitplc.comand
Summit can be followed on Twitter (@summitplc).
Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski (US office) | Tel: +44 (0)1235 443 951 +1 617 294 6607 |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781 235 3060 mavery@macbiocom.com |
Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
distributed by |